Toro, DBV Technologies, Udemy, ABM Industries, and Other Major Stocks Rising on Wednesday
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining over 150 points, while several companies, including Toro Co, reported better-than-expected quarterly earnings, leading to significant stock price increases.
Notable Stock Gains: Toro Co's shares rose 7% after reporting earnings of 91 cents per share, while DBV Technologies saw a 35.5% increase following positive trial results. Other companies like Udemy and Kodiak Sciences also experienced substantial gains.
Sector Highlights: Cannabis-related stocks surged after reports of potential reclassification of marijuana, with Canopy Growth Corp gaining 16.2%. Lithium-related stocks also rose following the cancellation of mining permits in Yichun.
Company Announcements and Upgrades: Several companies, including Recursion Pharmaceuticals and Two Harbors Investment Corp, saw stock price increases due to upgrades and acquisition announcements, reflecting positive investor sentiment.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on KOD
About KOD
About the author

BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.

Kodiak Sciences to Present at J.P. Morgan Conference on January 12, 2026
- Conference Presentation: Kodiak Sciences will present at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing its latest advancements in retinal disease treatments, which is expected to attract investor and industry attention.
- Clinical Research Progress: The company is advancing three late-stage clinical programs, with Tarcocimab and KSI-501 targeting the $15 billion anti-VEGF market, and topline data readouts expected in Q1 and Q3 2026, potentially impacting market positioning.
- New Drug Development: KSI-101, a bispecific protein, is undergoing two BLA clinical trials for Macular Edema Secondary to Inflammation, with data expected in Q4 2026 and Q2 2027, which could further enrich the product pipeline if successful.
- Market Potential: Kodiak Sciences is committed to developing transformative therapeutics aimed at addressing the leading causes of blindness globally, and with the release of clinical data, the company is poised to capture a larger market share in the biotechnology sector.








